Black Rock Inc. Equillium, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Equillium, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 38,317 shares of EQ stock, worth $27,205. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,317

Previous 3,811 905.43%

Holding current value

$27,205

Previous $8,000 225.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.66 - $2.33 $22,773 - $80,398	34,506 Added 905.43%	38,317 $26,000
Q1 2024 May 10, 2024	SELL	$0.73 - $3.0 $8 - $36	-12 Reduced 0.31%	3,811 $8,000
Q4 2023 Feb 13, 2024	SELL	$0.48 - $0.74 $2,881 - $4,442	-6,003 Reduced 61.09%	3,823 $2,000
Q3 2023 Nov 13, 2023	BUY	$0.72 - $0.9 $73 - $91	102 Added 1.05%	9,826 $7,000
Q2 2023 Aug 11, 2023	SELL	$0.49 - $0.79 $21,718 - $35,015	-44,324 Reduced 82.01%	9,724 $7,000
Q1 2023 May 12, 2023	BUY	$0.56 - $1.24 $735 - $1,628	1,313 Added 2.49%	54,048 $39,000
Q4 2022 Feb 13, 2023	BUY	$0.83 - $2.26 $7,051 - $19,200	8,496 Added 19.2%	52,735 $55,000
Q3 2022 Nov 14, 2022	SELL	$1.93 - $3.14 $11,346 - $18,460	-5,879 Reduced 11.73%	44,239 $98,000
Q2 2022 Aug 12, 2022	BUY	$1.69 - $3.26 $18,284 - $35,269	10,819 Added 27.53%	50,118 $102,000
Q1 2022 May 12, 2022	SELL	$2.99 - $4.19 $4,332 - $6,071	-1,449 Reduced 3.56%	39,299 $123,000
Q4 2021 Feb 10, 2022	SELL	$3.77 - $6.99 $7,702 - $14,280	-2,043 Reduced 4.77%	40,748 $154,000
Q3 2021 Nov 09, 2021	SELL	$4.84 - $6.91 $3,334 - $4,760	-689 Reduced 1.58%	42,791 $292,000
Q2 2021 Aug 11, 2021	BUY	$5.11 - $7.64 $222,182 - $332,187	43,480 New	43,480 $256,000

Others Institutions Holding EQ

# of Institutions

Shares Held

11.3M

Call Options Held

Put Options Held

View Full List

About Equillium, Inc.

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $24.4M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

More about EQ

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account